Last updated: April 23, 2026
What suppliers make the API (Tenofovir Disoproxil Fumarate)
Tenofovir disoproxil fumarate (TDF) is typically supplied as the API by specialized generics and pharmaceutical ingredient manufacturers. In the market, procurement is commonly split across:
- API manufacturers (tenofovir disoproxil fumarate bulk supply)
- Key intermediates makers (e.g., tenofovir disoproxil, fumaric acid salt-forming capacity)
- Finished-dose contract manufacturers that source API from approved upstream suppliers
API supplier lists for TDF are not published in a single authoritative global roster. In practice, buyers select suppliers through controlled vendor qualification tied to pharmacopeial compliance and regulatory inspection history.
Which raw-material inputs drive supplier selection for TDF
TDF is produced by combining a tenofovir disoproxil base with fumaric acid (to form the fumarate salt). Supplier qualification therefore centers on four input categories:
| Input category |
Typical supplier type |
What buyers qualify |
| Tenofovir disoproxil (base) |
Specialty nucleoside reverse-transcriptase inhibitor API intermediates manufacturers |
Identity, impurity profile, residual solvents, polymorph control |
| Fumaric acid |
Bulk organic acids producers |
Compliance to pharmacopeia grades, trace heavy metals |
| Solvents and reagents |
GMP specialty chemical suppliers |
Residual solvent limits, impurity carryover risk |
| API finishing and salt formation |
API plants with salt-forming capability |
Particle size range, dissolution behavior, final impurity specs |
Which suppliers are commonly used for fumarate salt formation and fumaric acid
Fumaric acid is a commodity-grade chemical in many regions, with multiple qualified GMP suppliers. For TDF supply continuity, buyers typically prioritize:
- Guaranteed GMP documentation (or DMF/ASMF if applicable in their jurisdiction)
- Stable pricing and lot availability for fumaric acid
- Consistent impurity limits that match TDF API specifications
Which finished-dose manufacturers buy TDF API from upstream suppliers
TDF is used in tablets and combination products (e.g., with emtricitabine, lamivudine, or other antiretrovirals). Finished-dose manufacturers usually buy TDF API from qualified API vendors and may also run salt formation or final crystallization steps depending on the manufacturing license structure.
Procurement patterns:
- Large generics often run long-term API contracts with multiple backup suppliers
- Combination-product CMO/CDMO relationships tend to lock the API source once the dossier is filed, then add alternates via variation packages
What procurement evidence matters for TDF suppliers (regulatory and quality)
For TDF, supplier diligence typically requires alignment across:
- API specification: identity, assay, water content, residual solvents, specified impurities
- Polymorph and crystal form: salt form control for reproducible dissolution
- GMP compliance: inspection outcomes for API production sites
- Regulatory dossier support: DMF/ASMF availability for the API and major intermediates
How to screen TDF suppliers quickly (short list criteria)
For business and R&D sourcing, screen candidates using:
- GMP manufacturing site history in the relevant inspection regimes (US FDA, EMA, MHRA, or local equivalents).
- Ability to supply API with matching impurity profile to your target jurisdiction specs and label history.
- Supply continuity: multi-lot throughput, active manufacturing status, and documented ability to qualify alternate lots without major dossier disruption.
Market structure: API, intermediates, and CMOs
TDF supply is usually executed as a chain:
- Intermediates (tenofovir disoproxil chemistry) -> salt formation with fumaric acid -> finished API -> tablets/combination tablets via CMO/CDMO.
That chain structure drives how buyers choose suppliers:
- A supplier that is strong on intermediates but weak on salt-forming and final impurity control creates qualification risk.
- A supplier that is strong on finished tablets but weak on API control shifts risk back upstream.
Supplier decision points for high-stakes TDF programs
Key commercial and technical decision points:
- Route-to-specibility: whether the supplier can meet your impurity list and residual solvent limits with stable process control.
- Salt/crystal performance: whether the supplier’s fumarate form yields consistent dissolution in your finished-dose formulation.
- Regulatory transferability: whether your dossier structure can absorb changes in API site or API source.
Key Takeaways
- TDF supply is driven by upstream control of tenofovir disoproxil base, fumaric acid salt formation, and final impurity/spec performance.
- Supplier selection is usually won by validated GMP manufacturing history and ability to deliver consistent fumarate crystallinity and impurity profiles, not by name-only vendor lists.
- Fast screening focuses on API specification match, dossier support (DMF/ASMF when relevant), and supply continuity across multiple lots and production campaigns.
FAQs
-
Do buyers select different suppliers for API versus fumaric acid for TDF?
Yes. API vendors provide full API specifications and impurity control; fumaric acid is often sourced from commodity-qualified GMP suppliers, but the salt-forming step and impurity carryover are still controlled to match the TDF spec.
-
Is salt formation (fumarate) typically a major supplier qualification risk for TDF?
Yes. TDF depends on reproducible fumarate crystallinity and dissolution behavior, so salt formation and final crystallization steps are core qualification points.
-
Why do TDF dossier changes become harder when switching API suppliers?
Because API supplier changes can alter impurity profiles, residual solvents, polymorph behavior, and particle attributes, which can trigger variation requirements and additional comparability work.
-
What is the most critical upstream input besides fumaric acid?
Tenofovir disoproxil base (or closely related tenofovir disoproxil intermediate chemistry), because it defines most of the API impurity and identity risks after salt formation.
-
How do procurement teams structure backup supply for TDF?
They qualify at least one additional API manufacturer site (and sometimes alternative intermediates) to protect lot continuity while keeping impurity and dissolution performance within spec.
References
[1] FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. US FDA.
[2] European Medicines Agency. EPAR and product information for tenofovir-containing medicinal products. EMA.
[3] U.S. Pharmacopeia (USP). Tenofovir Disoproxil Fumarate monograph/specification. USP.
[4] British Pharmacopoeia (BP). Tenofovir Disoproxil Fumarate monograph/specification. BP.
